|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1998-12-3
|
|
pubmed:abstractText |
Gabapentin is widely approved as add-on therapy for epilepsy treatment for partial seizures with and without secondary generalization. To investigate the efficacy of gabapentin administered as monotherapy in patients with newly diagnosed partial epilepsy, a randomized double-blind trial was performed.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0028-3878
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
51
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1282-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9818846-Acetic Acids,
pubmed-meshheading:9818846-Adolescent,
pubmed-meshheading:9818846-Adult,
pubmed-meshheading:9818846-Aged,
pubmed-meshheading:9818846-Aged, 80 and over,
pubmed-meshheading:9818846-Amines,
pubmed-meshheading:9818846-Anticonvulsants,
pubmed-meshheading:9818846-Carbamazepine,
pubmed-meshheading:9818846-Child,
pubmed-meshheading:9818846-Cyclohexanecarboxylic Acids,
pubmed-meshheading:9818846-Dose-Response Relationship, Drug,
pubmed-meshheading:9818846-Double-Blind Method,
pubmed-meshheading:9818846-Epilepsies, Partial,
pubmed-meshheading:9818846-Female,
pubmed-meshheading:9818846-Humans,
pubmed-meshheading:9818846-Male,
pubmed-meshheading:9818846-Medical Records,
pubmed-meshheading:9818846-Middle Aged,
pubmed-meshheading:9818846-Seizures,
pubmed-meshheading:9818846-gamma-Aminobutyric Acid
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77.
|
|
pubmed:affiliation |
Walton Centre for Neurology and Neurosurgery, Liverpool, UK.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
